Cellectis Licenses TAL Technology from Iowa State | GenomeWeb

NEW YORK (GenomeWeb News) – Cellectis today announced two licensing agreements with Iowa State University granting the Paris-based genome engineering firm the rights to use inventions related to TAL effector-nucleases and monomeric TALENs.

The licenses allow Cellectis to use the technology in any field, it said. TALENs are sequence-specific DNA scissors that can be custom engineered to target and modify any gene of interest in any species.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.